This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

TAK-070

University of Tokyo

Drug Names(s): TAK-070

Description: TAK-070 is a non-peptidic lipophilic BACE inhibitor that inhibits secretion of Aß40/42 and stimulates sAPPa production.

Deal Structure: Takeda and University of Tokyo Hospital
Takeda finalized a contract to transfer TAK-070, which was previously developed by Takeda as a potential treatment of Alzheimer-type dementia, to the National University Corporation, The University of Tokyo. Based on the contract, Takeda shall receive an upfront payment and a certain rate of royalty from the sales generated through the University of Tokyo, if TAK-070 is commercialized. No other economic conditions are disclosed.

Partners: Takeda Pharmaceutical Company Ltd


TAK-070 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug